db 777
NEW YORK, Dec. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Light & Wonder, Inc. LNW resulting from allegations that Light & Wonder may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Light & Wonder securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=29678 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. WHAT IS THIS ABOUT: On September 24, 2024, the Las Vegas Review-Journal published an article entitled "Slot manufacturer scores major win against Las Vegas-based rival." It stated that "Aristocrat Technologies Inc.'s request for a preliminary injunction in its trade-secret and copyright infringement lawsuit against Light & Wonder" had been granted, and that the "order prohibits [Light & Wonder] from the ‘continued or planned sale, leasing, or other commercialization of Dragon Train,' which Aristocrat claims uses intellectual property developed for its Dragon Link and Lightning Link games." On this news, Light & Wonder common stock fell 19.49% on September 24, 2024. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.How to Leverage Gold as Collateral for Loans
Zimbabwe to Tighten Land Ownership Rules Under New Tenure SystemAmid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer ( PFE 2.29% ) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual. But does that make the stock a buy, or is there reason to be cautious? Let's dig into the details here and make a judgment. This new forecast is a mixed bag To begin, let's compare the new outlook issued by management for 2025 with its recent performance to get a sense of how significant the coming 12 months will be for shareholders. Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Per the updated projection for next year, the business anticipates bringing in revenue of as much as $64 billion, and adjusted diluted EPS of between $2.80 and $3.00. But here's where shareholders are apt to frown. According to the reaffirmed forecast for this year, 2024, the company expects to bring in as much as $64 billion in revenue, and as much as $2.95 in adjusted diluted EPS. See the issue? Even if things go well enough that sales and earnings end up in the upper ranges of management's forecasts, there won't be much in the way of top or bottom-line growth between 2024 and 2025. That means management's plan to implement $500 million in cost savings in 2025 will hardly make a dent. On the bright side, a separate cost-savings campaign dedicated to manufacturing specifically is expected to start to deliver in the second half of 2025, so that might make 2026 a bit better from an earnings perspective. Plus, the overlapping forecast for 2024 and 2025 are, to an extent, a mirage; after removing non-recurring items from this year's forecast performance, Pfizer thinks that its revenue could grow by as much as 5% and its adjusted diluted EPS by as much as 18% in 2025. Still, that isn't actually very reassuring, as management is frank that performing at the lower ends of its estimates would result in zero revenue growth and just 10% EPS growth year over year. The long term looks a bit better than the near term What should investors make of this update from management? For one, there hasn't been much discussion of how the business is going to grow faster in the near future than it is today, which suggests no upcoming major changes in strategy. The previously established goals of becoming more efficient, becoming a world leader in oncology drugs, and continuing to return capital to shareholders while reducing the company's debt burden are still in progress. Likewise, research and development (R&D) activities will continue to be fully funded, and while it hasn't been explicitly mentioned, there is a high probability that Pfizer will continue to look for opportunities to acquire promising biotechs or their pharmaceutical assets to bolster the pipeline. More importantly, shareholders need to brace themselves for another year of the stock being in the doldrums. There's no obvious pending catalyst that would enable big price appreciation. At the same time, if you're interested in collecting a dividend with a toothsome forward yield of 6.7%, right now looks like a great time to buy more shares or invest for the first time -- except for the fact that Pfizer is paying out significantly more than it's generating in earnings; its payout ratio is a lofty 223%. The risk of the dividend getting cut is not very high at the moment, but if weak growth continues for a couple of years longer, it could be on the table, especially if there's an unlucky run of late-stage programs that fail in the pipeline. With all of the above in mind, this stock is still worth buying, provided that you're willing to hold onto it through the slow period ahead. Just be aware that the risk is higher here than it would normally be with a big pharma stock, as this giant looks like it's moving slower than its shareholders might prefer.
Assad family’s iron-grip rule on Syria toppled as insurgents take control of Damascus
After Trump's Project 2025 denials, he is tapping its authors and influencers for key roles
Simo Valakari explains training ground graft behind St Johnstone’s first headed goal of season – and why it should lead to moreAP Business SummaryBrief at 2:22 p.m. EST
